Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Metrics to compare | MBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.1x | −3.6x | −0.5x | |
PEG Ratio | 0.02 | 0.02 | 0.00 | |
Price/Book | 1.1x | 0.7x | 2.6x | |
Price / LTM Sales | 1.8x | 2.1x | 3.3x | |
Upside (Analyst Target) | 127.3% | 108.7% | 47.1% | |
Fair Value Upside | Unlock | 13.9% | 5.8% | Unlock |